Botanical Monographs, Marketing Exclusivity Discussed By IoM Committee
This article was originally published in The Tan Sheet
Executive Summary
Botanical products should either conform to established monographs or be subjected to clinical trials that prove their safety and efficacy, health policy analyst Rowena Richter said at an IoM Committee meeting on U.S. consumers' use of complementary & alternative medicine held in Washington, D.C. June 30